UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2367-2377

  Christoph, Sandra ^a,b   DeRyckere, Deborah ^a   Schlegel, Jennifer ^a   Frazer, J Kimble ^c   Batchelor, Lance A ^c   Trakhimets, Alesia Y ^d   Sather, Susan ^a   Hunter, Debra M ^f   Cummings, Christopher T ^e   Liu, Jing ^e   Yang, Chao ^e   Kireev, Dmitri ^e   Simpson, Catherine ^e   Norris Drouin, Jacqueline ^e   Hull Ryde, Emily A ^e   Janzen, William P ^e,f   Johnson, Gary L ^f   Wang, Xiaodong ^e   Frye, Stephen V ^e,f   Earp Iii, H Shelton ^f   Graham, Douglas K ^a,g   more..

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; METHYLCELLULOSE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; UNC 569; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER REGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; COLONY FORMATION; COLORIMETRY; CONTROLLED STUDY; DRUG EFFICACY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CULTURE; LYMPHOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; WESTERN BLOTTING; ZEBRA FISH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; JURKAT CELLS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RHABDOID TUMOR; TERATOMA; ZEBRAFISH;

EID: 84887421432     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0445     Document Type: Article

References (38)

1. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36:277-85.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Pui C, Mullighan C, Evans W, Relling M. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012;120:1165-74.
4. Landier W, Bhatia S. Cancer survivorship: a pediatric perspective. Oncologist 2008;13:1181-92.
5. Oeffinger K, Mertens A, Sklar C, Kawashima T, Hudson M, Meadows A, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82.
6. Linger R, Keating A, Earp H, Graham D. TAMreceptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008;100:35-83.
7. Brandao L, Migdall-Wilson J, Eisenman K, Graham D. TAMreceptors in leukemia: expression, signaling, and therapeutic implications. Crit Rev Oncog 2011;16:47-63.
8. Linger R, Keating A, Earp H, Graham D. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 2010;14:1073-90.
9. Yeoh E, Ross M, Shurtleff S, Williams W, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-43.
10. Keating A, Salzberg D, Sather S, Liang X, Nickoloff S, Anwar A, et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene 2006;25:6092-100.
11. Graham D, Salzberg D, Kurtzberg J, Sather S, Matsushima G, Keating A, et al. Ectopic expression of the proto-oncogene Mer in pediatric Tcell acute lymphoblastic leukemia. Clin Cancer Res 2006;12:2662-9.
12. Brandao L, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, et al. Inhibition of MerTK increases the chemosensitivity and decreases the oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer J 2013;3:e101.
13. Cummings C, Deryckere D, Earp H, Graham D. Molecular pathways: MERTK signaling in cancer. Clin Cancer Res. 2013 Aug 7. [Epub ahead of print].
14. Levy J, Thorburn A. Modulation of pediatric brain tumor autophagy and chemosensitivity. J Neurooncol 2012;106:281-90.
15. Ginn K, Gajjar A. Atypical teratoid/rhabdoid tumor: current therapy and future directions. Front Oncol 2012;2:114.
16. O'Brien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
17. O'Hare T, Deininger M, Eide C, Clackson T, Druker B. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome- positive leukemia. Clin Cancer Res 2011;17:212-21.
18. Goldman J. Ponatinib for chronic myeloid leukemia. N Engl J Med 2012;367:2148-9.
19. Brassard M, Rondeau G. Role of vandetanib in the management of medullary thyroid cancer. Biologics 2012;6:59-66.
20. Ryan Q, Ibrahim A, Cohen M, Johnson J, Ko C, Sridhara R, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER- 2. Oncologist 2008;13:1114-9.
21. Wang Y, Schmid-Bindert G, Zhou C. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther Adv Med Oncol 2012;4:19-29.
22. Wood L. Sunitinib malate for the treatment of renal cell carcinoma. Expert Opin Pharmacother 2012;13:1323-36.
23. Zauli G, Voltan R, Tisato V, Secchiero P. State of the art of the therapeutic perspective of sorafenib against hematological malignancies. Curr Med Chem 2012;19:4875-84.
24. Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
25. Huang X, Finerty PJ, Walker J, Butler-Cole C, Vedadi M, Schapira M, et al. Structural insights into the inhibited states of the Mer receptor tyrosine kinase. J Struct Biol 2009;165:88-96.
26. Verma A, Warner S, Vankayalapati H, Bearss D, Sharma S. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 2011;10:1763-73.
27. Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley M, et al. Discovery of novel small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia. ACS Med Chem Lett 2012;3:129-34.
28. Masters J, Thomson J, Daly-Burns B, Reid Y, Dirks W, Packer P, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 2001;98: 8012-7.
29. Linger R, Cohen R, Cummings C, Sather S, Migdall-Wilson J, Middleton D, et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 2013;32:3420-31.
30. Mahajan N, Earp H. An SH2 domain-dependent, phosphotyrosineindependent interaction between Vav1 and the Mer receptor tyrosine kinase: a mechanism for localizing guanine nucleotide-exchange factor action. J Biol Chem 2003;278:42596-603.
31. Gutierrez A, Grebliunaite R, Feng H, Kozakewich E, Zhu S, Guo F, et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med 2011;208: 1595-603.
32. Langenau D, Ferrando A, Traver D, Kutok J, Hezel J, Kanki J, et al. In vivo tracking of T cell development, ablation, and engraftment in transgenic zebrafish. Proc Natl Acad Sci U S A 2004;101:7369-74.
33. Ridges S, Heaton W, Joshi D, Choi H, Eiring A, Batchelor L, et al. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood 2012;119:5621-31.
34. Shan X, Czar M, Bunnell S, Liu P, Liu Y, Schwartzberg P, et al. Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol Cell Biol 2000;20:6945-57.
35. Keating A, Kim G, Jones A, Donson A, Ware K, Mulcahy J, et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 2010;9:1298-307.
36. Linger R, Lee-Sherick A, Deryckere D, Cohen R, Jacobsen K, McGranahan A, et al. Mer receptor tyrosine kinase is a therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood 2013;122: 1599-609.
37. Gardner S, Asgharzadeh S, Green A, Horn B, McCowage G, Finlay J. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid/ rhabdoid tumors. Pediatr Blood Cancer 2008;51:235-40.
38. Knipstein J, Birks D, Donson A, Alimova I, Foreman N, Vibhakar R. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. Neuro Oncol 2012;14:175-83.